• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在癌症一期临床试验后评估推荐剂量下的毒性概率。

Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.

作者信息

O'Quigley J

机构信息

Department of Mathematics, University of California, San Diego, La Jolla 92093-0112.

出版信息

Biometrics. 1992 Sep;48(3):853-62.

PMID:1420845
Abstract

The problem of point and interval estimation following a Phase I trial, carried out according to the scheme outlined by O'Quigley, Pepe, and Fisher (1990, Biometrics 46, 33-48), is investigated. A reparametrization of the model suggested in this earlier work can be seen to be advantageous in some circumstances. Maximum likelihood estimators, Bayesian estimators, and one-step estimators are considered. The continual reassessment method imposes restrictions on the sample space such that it is not possible for confidence intervals to achieve exact coverage properties, however large a sample is taken. Nonetheless, our simulations, based on a small finite sample of 20, not atypical in studies of this type, indicate that the calculated intervals are useful in most practical cases and achieve coverage very close to nominal levels in a very wide range of situations. The relative merits of the different estimators and their associated confidence intervals, viewed from a frequentist perspective, are discussed.

摘要

研究了按照奥奎利、佩佩和费舍尔(1990年,《生物统计学》46卷,33 - 48页)概述的方案进行的I期试验后的点估计和区间估计问题。在某些情况下,可以看出对这项早期工作中提出的模型进行重新参数化是有利的。考虑了最大似然估计量、贝叶斯估计量和一步估计量。连续重新评估方法对样本空间施加了限制,使得无论样本量多大,置信区间都不可能实现精确的覆盖特性。尽管如此,我们基于20个小有限样本(在这类研究中并非不典型)的模拟表明,计算出的区间在大多数实际情况下是有用的,并且在非常广泛的情况下实现的覆盖范围非常接近名义水平。从频率主义的角度讨论了不同估计量及其相关置信区间的相对优点。

相似文献

1
Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer.在癌症一期临床试验后评估推荐剂量下的毒性概率。
Biometrics. 1992 Sep;48(3):853-62.
2
Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples.小样本最大耐受剂量下毒性概率的区间估计。
Stat Med. 2003 Jun 15;22(11):1829-36. doi: 10.1002/sim.1443.
3
Continual reassessment method: a likelihood approach.连续重新评估法:一种似然性方法。
Biometrics. 1996 Jun;52(2):673-84.
4
A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.比较Ⅰ期癌症试验中连续评估方法的模型选择。
Stat Med. 2009 Oct 30;28(24):3012-28. doi: 10.1002/sim.3682.
5
Small-sample confidence sets for the MTD in a phase I clinical trial.I期临床试验中最大耐受剂量(MTD)的小样本置信集
Biometrics. 1993 Dec;49(4):1117-25.
6
Sensitivity of dose-finding studies to observation errors.剂量探索研究对观测误差的敏感性。
Contemp Clin Trials. 2009 Nov;30(6):523-30. doi: 10.1016/j.cct.2009.06.008. Epub 2009 Jul 4.
7
Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.I期临床试验中的异质性:使用连续重新评估法的先验诱导和计算
Stat Med. 2001 Mar 30;20(6):867-82. doi: 10.1002/sim.701.
8
Dose-escalation designs in oncology: ADEPT and the CRM.肿瘤学中的剂量递增设计:自适应剂量递增设计(ADEPT)与连续重新评估方法(CRM)
Stat Med. 2008 Nov 20;27(26):5345-53; discussion 5354-5. doi: 10.1002/sim.3403.
9
Two-sample continual reassessment method.
J Biopharm Stat. 1999 Mar;9(1):17-44. doi: 10.1081/BIP-100100998.
10
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.用于癌症I期临床试验的灵活贝叶斯方法。具有过量控制的剂量递增。
Stat Med. 2005 Jul 30;24(14):2183-96. doi: 10.1002/sim.2106.

引用本文的文献

1
Adaptive Phase 1 Design in Radiation Therapy Trials.放射治疗试验中的适应性1期设计。
Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):493-499. doi: 10.1016/j.ijrobp.2022.02.031.
2
Adaptive prior variance calibration in the Bayesian continual reassessment method.贝叶斯连续再评估方法中的自适应先验方差校准。
Stat Med. 2013 Jun 15;32(13):2221-34. doi: 10.1002/sim.5621. Epub 2012 Sep 17.
3
Continual Reassessment and Related Dose-Finding Designs.连续重新评估及相关剂量探索设计
Stat Sci. 2010;25(2):202-216. doi: 10.1214/10-STS332.
4
High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART).大剂量洛伐他汀治疗急性缺血性卒中:他汀类药物治疗急性恢复试验(NeuSTART)I期剂量递增神经保护的结果
Cerebrovasc Dis. 2009;28(3):266-75. doi: 10.1159/000228709. Epub 2009 Jul 16.
5
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.在I期剂量探索研究中,持续重新评估方法与标准3+3剂量递增方案的全面比较。
Clin Trials. 2008;5(5):465-77. doi: 10.1177/1740774508096474.
6
Phase I and pharmacokinetic study of intraperitoneal topotecan.腹腔注射拓扑替康的I期及药代动力学研究
Invest New Drugs. 1998;16(2):147-53. doi: 10.1023/a:1006045125018.